Main page screenshot of
Reviewed on Sep 23st, 2019

Geron: Home

Geron is a biopharmaceutical company developing first-in-class cancer therapeutics. Imetelstat, the company’s lead telomerase inhibitor, is currently being evaluated in four Phase 2 clinical oncology studies for the following indications: non-small cell lung cancer, breast cancer, essential thrombocythemia and multiple myeloma. GRN1005, an LRP-directed peptide-drug conjugate, is being evaluated in two Phase 2 clinical trials, one for brain metastases arising from non-small cell lung cancer an...

Competing rank

Related searches

Most popular

Latest searches